All Issue

2026 Vol.56, Issue 1 Preview Page

Original Article

In Vitro Activity of Ceftaroline Against Multidrug-Resistant Bacteria in Niger: Resistance Trends and Clinical Implications
Issoufou Noma Massir12*
,
Yacouba Abdourahamane13
,
Tapha Ounoussa1
,
Moussa Harouna1
,
Natatou Ibrahim Balkissa1
,
Mahaman Moustapha Lamine2
,
Ousmane Abdoulaye4
,
Brah Souleymane15
,
Mahamadou Doutchi6
,
Ibrahim Mamane Laminou7
1Laboratoire National de Référence sur la Surveillance de Résistance aux Antimicrobiens, Hôpital National Amirou Boubacar Diallo, Niamey, Niger
2Laboratoire de Recherche Clinique et des Systèmes de Santé, Université André Salifou, Zinder, Niger
3Département des sciences biologiques appliquées, Faculté des sciences de la santé, Université Abdou Moumouni, Niamey, Niger
4Département des sciences biologiques appliquées, Faculté des sciences de la santé, Université Dan Dicko Dankoulodo, Maradi, Niger
5Département de médecine et des spécialités médicales, Faculté des sciences de la santé, Université Abdou Moumouni, Niamey, Niger
6Département de médecine et des spécialités médicales, Faculté des sciences de la santé, Université André Salifou, Zinder, Niger
7Centre de Recherche Médicale et Sanitaire, Niamey, Niger
*drmantcha425@gmail.com
31 March 2026. pp. 13-23
PDF XML Citation
Abstract

Multidrug-resistant bacteria, including extended-spectrum β-lactamase-producing Enterobacterales and methicillin-resistant Staphylococcus aureus, pose a major therapeutic challenge in Niger. Ceftaroline, a fifth-generation cephalosporin, offers potential activity against these pathogens. This study aimed to evaluate the in vitro activity of ceftaroline against multidrug-resistant bacteria isolated in Niger and to identify factors associated with resistance. A prospective cross-sectional study was conducted from January to August 2025. A total of 212 non-duplicate multidrug- resistant isolates (160 extended-spectrum β-lactamase-producing Enterobacterales, 52 methicillin-resistant Staphylococcus aureus) were tested using the disk diffusion method. Logistic regression was used to identify factors independently associated with ceftaroline resistance. The overall resistance rate to ceftaroline was 69.3% (147/ 212). extended-spectrum β-lactamase-producing Enterobacterales isolates exhibited a very high resistance rate (80.6%), whereas methicillin-resistant Staphylococcus aureus (MRSA) isolates showed lower resistance (34.6%). In multivariate analysis, extended-spectrum β-lactamase-producing Enterobacterales phenotype (Odds Ratio=5.03; 95% Confidence Interval=2.13-11.83), concurrent resistance to aminoglycosides (Odds Ratio=2.55; 95% Confidence Interval=1.21-5.33), fosfomycin (Odds Ratio=3.42; 95% Confidence Interval=1.01-11.50), and cotrimoxazole (Odds Ratio=3.97; 95% Confidence Interval=1.20-13.02) were significant factors independently associated with ceftaroline resistance. This first study conducted in Niger reveals an alarming rate of in vitro resistance to ceftaroline among multidrug- resistant bacteria, primarily extended-spectrum beta-lactamase-producing Enterobacterales. Ceftaroline should not be used empirically for suspected infections with these pathogens in this context. Its use against methicillin-resistant Staphylococcus aureus must be guided by susceptibility testing. These data call for revisions to therapeutic protocols and reinforcement of antimicrobial stewardship strategies.

Keywords
Ceftaroline
Multidrug-resistant bacteria
Niger
References
1

WHO. Antimicrobial Resistance: World Health Organization. 2021. Available at https://www.who.int/fr/news-room/fact-sheets/detail/antimicrobial-resistance [accessed on 22 Oct 2024].

2

Abdoulaye O, Bacha BSM, Aghali NH, Abdoulaye I, Abdoulaye MB, Lo G, et al. Profile of multidrug-resistant clinical bacterial isolates at the National Hospital of Zinder (NHZ), Niger Republic in 2021. African Journal of Clinical and Experimental Microbiology. 2022;23(4):369‑377.

10.4314/ajcem.v23i4.5
3

Tapha O, Degbey CC, Yacouba A, Mahouna Tchioundjro E, Nadakou NT, Alkassoum Salifou I, et al. Antimicrobial use in hospitalized patients: a point prevalence survey across four tertiary hospitals in Niger. JAC Antimicrob Resist. 2024;6(5):dlae175.

10.1093/jacamr/dlae17539478985PMC11523492
4

Kempf M, Arhin FF, Kuraieva A, Utt E. In vitro Activity of Ceftaroline Against Isolates of Gram-Positive Bacteria from Patients with Bloodstream Infections Collected as a Part of ATLAS Between 2017 and 2020. Infect Drug Resist. 2024; 17:343‑354.

10.2147/IDR.S42300438312522PMC10838500
5

Jacqueline C, Tattevin P. Ceftaroline, a new cephalosporin active against methicillin-resistant Staphylococcus aureus: experimental and clinical data, therapeutic perspectives. Anti-infectious Journal. 2012;14(1):3‑10.

6

Karlowsky JA, Hackel MA, Bouchillon SLK, Lowman W, Kotb REM, Mohamed N, et al. In vitro activity of ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in the Middle East and Africa: AWARE global surveillance programme 2015-2018. J Glob Antimicrob Resist. 2021;24:249‑256.

10.1016/j.jgar.2020.12.013
7

Sader HS, Flamm RK, Jones RN. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010). Diagn Microbiol Infect Dis. 2013;76(1):61‑68.

10.1016/j.diagmicrobio.2013.01.005
8

Karlowsky JA, Biedenbach DJ, Bouchillon SK, Hackel M, Iaconis JP, Sahm DF. In vitro activity of Ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in African and Middle Eastern countries: AWARE global surveillance program 2012-2014. Diagn Microbiol Infect Dis. 2016;86(2): 194‑199.

10.1016/j.diagmicrobio.2016.07.012
9

Lopera C, Monzó P, Aiello TF, Chumbita M, Peyrony O, Gallado-Pizarro A, et al. Prevalence and impact of multidrug- resistant bacteria in solid cancer patients with bloodstream infection: a 25-year trend analysis. Microbiol Spectr. 2024;12(10):e0296123.

10.1128/spectrum.02961-2339194256PMC11448387
10

EUCAST. Clinical breakpoints - breakpoints and guidance. 2024. Available at https://www.eucast.org/clinical_breakpoints [accessed on 27 Nov 2024].

11

Clark C, McGhee P, Appelbaum PC, Kosowska-Shick K. Multistep Resistance Development Studies of Ceftaroline in Gram-Positive and Gram-Negative Bacteria. Antimicrob Agents Chemother. 2011;55(5):2344‑2351.

10.1128/AAC.01602-1021343467PMC3088212
12

Flamm RK, Sader HS, Farrell DJ, Jones RN. Summary of Ceftaroline Activity against Pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program. Antimicrob Agents Chemother. 2012;56(6):2933‑2940.

10.1128/AAC.00330-1222470115PMC3370782
13

Sader HS, Flamm RK, Streit JM, Farrell DJ, Jones RN. Ceftaroline Activity against Bacterial Pathogens Frequently Isolated in U.S. Medical Centres: Results from Five Years of the AWARE Surveillance Program. Antimicrob Agents Chemother. 2015;59(4):2458‑2461.

10.1128/AAC.04614-1425645844PMC4356765
14

Cercenado E, Morosini MI. Antimicrobial spectrum of ceftaroline. In vitro activity against methicillin-resistant Staphylococci. Enferm Infecc Microbiol Clin. 2014;32 Suppl 2:8‑14.

15

Duplessis C, Crum-Cianflone NF. Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphy lococcus aureus (MRSA). Clin Med Rev Ther. 2011;3:a2466.

10.4137/CMRT.S163721785568PMC3140339
16

Omar MH, Kilale AM, Rashid HK, Mwakapeje ER, Onoka IM, Gimbi AA. Prevalence and risk factors for extended- spectrum β-lactamase-producing antimicrobial-resistant E. coli in urinary tract infections among inpatients in the tertiary hospitals in Zanzibar (Tanzania): a prospective cross-sectional study. Pan Afr Med J. 2024; 47:193.

10.11604/pamj.2024.47.193.3792039119113PMC11308945
17

Ng RWY, Yang L, Lau SH, Hawkey P, Ip M. Global prevalence of human intestinal carriage of ESBL-producing E. coli during and after the COVID-19 pandemic. JAC Antimicrob Resist. 2025;7(1):dlaf001.

10.1093/jacamr/dlaf00139866328PMC11759295
18

Sallam HH, Ramadan AA, Attia NM, ElBaradei A, Shawky SM, El-Kholy MA. Ceftaroline Exhibits Promising In Vitro Activity Against Methicillin-Resistant Staphylococcus aureus Clinical Isolates from Alexandria, Egypt. Int J Microbiol. 2025; 2025:4558662.

10.1155/ijm/455866240420854PMC12105897
19

Karlowsky JA, Biedenbach DJ, Bouchillon SK, Hackel M, Iaconis JP, Sahm DF. In vitro activity of Ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in African and Middle Eastern countries: AWARE global surveillance program 2012-2014. Diagn Microbiol Infect Dis. 2016;86(2):194-199.

10.1016/j.diagmicrobio.2016.07.012
20

Schaumburg F, Peters G, Alabi A, Becker K, Idelevich EA. Missense mutations of PBP2a are associated with reduced susceptibility to ceftaroline and ceftobiprole in African MRSA. J Antimicrob Chemother. 2016;71(1):41‑44.

10.1093/jac/dkv325
21

Moumouni A, Diagbouga S, Nadembèga CWM, Dabire A, Salah F, et al. Quinolone Resistance (qnr) genes in fecal carriage of extended-spectrum beta-lactamases producing Enterobacteria isolated from children in Niger. Curr Res Microbiol Biotechnol. 2017;5(1):953-957.

Information
  • Publisher :The Korean Society for Microbiology and The Korean Society of Virology
  • Publisher(Ko) :대한미생물학회‧대한바이러스학회
  • Journal Title :JOURNAL OF BACTERIOLOGY AND VIROLOGY
  • Volume : 56
  • No :1
  • Pages :13-23
  • Received Date : 2025-12-23
  • Revised Date : 2026-03-03
  • Accepted Date : 2026-03-08
  • DOI :https://doi.org/10.4167/jbv.2026.56.1.013
Journal Informaiton JOURNAL OF BACTERIOLOGY AND VIROLOGY JOURNAL OF BACTERIOLOGY AND VIROLOGY
  • NRF
  • 임플란트학회 전용 배너
  • KOFST
  • crossref crossmark
  • crossref cited-by
  • crossref funder-registry
  • crosscheck
  • orcid
  • open access
  • ccl
Journal Informaiton Journal Informaiton - close